Implementation of Shorter All-Oral MDR-TB Regimens in the UK

Overview

The UK has successfully transitioned from the 18-month MDR-TB regimen to shorter 6-9 month bedaquiline-based all-oral regimens, achieving treatment success rates between 84% and 93%. This shift involved overcoming practical barriers through expert oversight, funded access pathways, and standardized monitoring, improving patient adherence and clinical capacity.

Background

Multidrug-resistant tuberculosis (MDR-TB) traditionally required lengthy 18-month treatment regimens often including injectable drugs with significant toxicity. Recent clinical trials such as Nix, ZeNix, TB-PRACTECAL, BEAT-TB, and endTB have demonstrated that shorter, all-oral regimens based on bedaquiline can achieve favorable outcomes with better tolerability. Despite these advances, challenges remain in drug licensing, cost, supply, and patient eligibility. The UK experience provides a model for implementing these regimens within a complex healthcare system.

Data Highlights

Key Findings

• Shorter bedaquiline-based regimens (6-9 months) have replaced the traditional 18-month MDR-TB treatment in the UK.
• Treatment success rates in clinical trials range from approximately 84% to 93%, with improved tolerability compared to injectable regimens.
• Implementation required expert case-by-case oversight, national clinical advice services, and formal commissioning policies to fund and approve high-cost, unlicensed drugs.
• Standardized drug-specific monitoring guidance supports safe prescribing, particularly monitoring for linezolid toxicity.
• Shorter regimens reduce pill burden, adverse events, and time on directly observed therapy, enhancing adherence and clinical capacity.
• Social policies ensuring free TB treatment regardless of immigration status and support for vulnerable populations are integral to successful implementation.

Clinical Implications

Clinicians should consider shorter all-oral bedaquiline-based regimens as the preferred treatment for eligible MDR-TB patients, balancing efficacy with improved tolerability. Implementation requires coordinated specialist oversight, access pathways for high-cost drugs, and vigilant toxicity monitoring, especially for linezolid. Additionally, addressing social determinants and ensuring equitable access are critical to treatment success.

Conclusion

The UK experience demonstrates that shorter, all-oral MDR-TB regimens can be safely and effectively implemented through coordinated health system strategies, improving outcomes and patient adherence. This model highlights the necessary infrastructure and policy frameworks to support the transition from longer, injectable-based therapies.

References

1. BMJ Open Respiratory Research -- The 18-Month MDR-TB Regimen Has a Successor